Doctronic vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Doctronic became the first AI to legally renew prescriptions in the US (190-med formulary, Utah); raised $40M Series B with 300K+ visitors as it expands state by state (March 2026).
About
Doctronic is a US-based AI telehealth company that has built a regulatory-compliant AI platform for medical consultations and prescription services. The company made history by becoming the first AI to legally renew prescriptions in the United States, initially operating in Utah under a pioneering regulatory framework that allows AI-assisted prescribing for a defined formulary of medications. Doctronic's platform enables patients to consult with an AI for common, well-understood health conditions and receive prescriptions for up to 190 medications without requiring a synchronous visit with a human physician.\n\nDoctronic's platform is designed to navigate the complex intersection of AI capability, medical regulation, and patient safety. Its AI conducts structured medical history intake, symptom assessment, and contraindication screening before generating prescription recommendations that are reviewed within a compliance framework. The platform targets patients seeking convenient, affordable access to prescription renewals and routine care for chronic and common conditions—a massive market given the primary care shortage in the United States. Doctronic operates at the forefront of AI in regulated healthcare, demonstrating that AI can deliver clinically appropriate care within legal guardrails.\n\nDoctronic raised a $40M Series B in 2026 to accelerate geographic expansion and broaden its formulary and condition coverage. With over 300,000 visitors to its platform, Doctronic has demonstrated real consumer demand for AI-mediated healthcare access. The company's Utah-first strategy allowed it to build a compliant, proven model before pursuing expansion to additional states with favorable telehealth regulations. As regulatory frameworks for AI in medicine evolve, Doctronic is positioned as a first-mover with a defensible regulatory and clinical knowledge base.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.